Updates are available Erratum dated 2022-04-01
Click to view Erratum: https://doi.org/10.1016/s1470-2045(22)00131-0
Updates are available Erratum dated 2022-09-01
Click to view Erratum: https://doi.org/10.1016/s1470-2045(22)00493-4
-
Authors
Richardson, Paul G
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H Miles
Malinge, Laure
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(22)00019-5
Content Type: article
Copyright: © 2022 Elsevier Ltd. All rights reserved.
